The new cardiac mapping platform is developed to support physicians in the better treatment of abnormal heart rhythms called cardiac arrhythmias
Abbott has secured approval from the US Food and Drug Administration (FDA) for its EnSite X EP System with EnSite Omnipolar Technology (OT).
Available in the US and across Europe, the new cardiac mapping platform has been developed to support physicians in the better treatment of abnormal heart rhythms called cardiac arrhythmias.
By creating detailed three-dimensional maps of the heart, the system helps physicians to detect and treat areas of the heart where abnormal rhythms originate.
The system features EnSite OT that enables to leverage the Advisor HD Grid Catheter to deliver true electrograms (EGMs) irrespective of how the catheter is oriented within the heart.
With a capacity to sample EGMs in 360 degrees, the EnSite X EP System with EnSite OT allows to map one million points in the heart and offer more precise location of treatment areas.
Abbott electrophysiology senior vice president Mike Pederson said: “We developed the EnSite X System with EnSite OT to enhance the utility of our unique Advisor HD Grid catheter and allow doctors to quickly and accurately create real-time, stable, three-dimensional models of the heart.
“These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue.”
To support the development of EnSite X System with EnSite OT, the company has created the platform that can be upgraded through software.
The EnSite X EP System with EnSite OT is claimed to be the first system, which allows physicians to select between two methods of cardiac visualisation.
In September last year, Abbott secured approval from the FDA for its Epic Plus and Epic Plus Supra Stented Tissue Valves to aid aortic or mitral valve disease treatment.